<< Back to Chemical Sampling Information
Synonyms: N-α-dimethyl-Benzeneethanamine; (α R)-N-α-dimethyl-Benzeneethanamine; (α S)-N-α-dimethyl-Benzeneethanamine; N-α-dimethyl-Benzeneethanamine hydrochloride
OSHA IMIS Code Number: M315
Chemical Abstracts Service (CAS) Registry Number: 51-57-0 (Benzeneethanamine
, N-alpha-dimethyl-, hydrochloride);
537-46-2 (Benzeneethanamine, N-alpha-dimethyl-, (alpha S)-);
7632-10-2 (Benzeneethanamine, N-alpha-dimethyl-);
33817-09-3 (Benzeneethanamine, N-alpha-dimethyl-, (alpha R)-)
NIOSH Registry of Toxic Effects of Chemical Substances (RTECS) Identification Number: SH4900000
Chemical Description and Physical Properties:
varies with chemical composition
Potential Symptoms: Insomnia, depression, irritability, paranoia, hallucination; stroke; myocardial infarction, cardiac arrhythmia; hyperthermia in overdose
Health Effects: Nervous system disturbances (HE7); Chronic (Cumulative) Toxicity---Heart abnormalities; abuse liability (HE3)
Affected Organs: CNS, cardiovascular system
- OSHA does not have a PEL for methamphetamine.
- Methamphetamine is a Schedule II controlled substance (21 CFR 1308.12), which is approved by the FDA for the treatment of attention deficit disorder with hyperactivity and exogenous obesity.
- The mean elimination half-life of methamphetamine was approximately 11 hours by intravenous, intranasal and inhaled (smoked) routes of administration in eight experienced users.
- Injuries have occurred to first responders (police officers, emergency medical staff, fire fighters) from chemicals used in illicit methamphetamine-producing laboratories, including hydrochloric acid, ammonia, phosphine, and diethyl ether.
- Anglin, M.D., Burke, C., Perrochet, B., Stamper, E. and Dawud-Noursi, S.: History of the methamphetamine problem. J. Psychoactive Drugs 32(2): 137-141, 2000.
- Burgess, J.L.: Phosphine exposure from a methamphetamine laboratory investigation. J. Toxicol. Clin. Toxicol. 39(2): 165-168, 2001.
- Fuller, K.: A dangerous business. Occup. Health Saf. 74(9): 188-191, 2005.
- Harris, D.S., Boxenbaum, H., Everhart, E.T., Sequeira, G., Mendelson, J.E. and Jones, R.T.: The bioavailability of intranasal and smoked methamphetamine. Clin. Pharmacol. Ther. 74(5): 475-486, 2003.
- Matoba, R.: [Cardiac lesions in methamphetamine abusers.] Nippon Hoigaku Zassi 55(3): 321-330, 2001. (English abstract in PubMed, PMID: 11905041.)
- No author: Public health consequences among first responders to emergency events associated with illicit methamphetamine laboratories --- selected states, 1996-1999. MMWR Weekly 49(45): 1021-1024, 2000.
- Schepers, R.J.F., Oyler, J.M., Joseph, R.E., Jr., Cone, E.J., Moolchan, E.T. and Huestis, M.A.: Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin. Chem. 49(1): 121-132, 2003.
- Uemura, K., Sorimachi, Y., Yashiki, M. and Yoshida, K.: Two fatal cases involving concurrent use of methamphetamine and morphine. J. Forensic Sci. 48(5): 1179-1181, 2003.
Date Last Revised: 04/13/2006
On-Site Sampling Techniques/Methods:
- note: On-site surface sampling test kits are commercially available. OSHA neither endorses these kits nor recommends their use. The effectiveness and applicability of these kits are the responsibility of the user.
** All Trademarks are the property of their respective owners.